Efficacy of Early Ivermectin Administration in Acute Chikungunya Virus Infection: A Multicenter, Open-Label, Randomized Controlled Trial

BACKGROUND: Acute and chronic joint pain is the hallmark of chikungunya virus (CHIKV) infection, often progressing to debilitating persistent joint pain. No approved antiviral therapy is available. We evaluated the clinical and virological efficacy of early ivermectin administration in acute CHIKV infection. METHODS: This open-label, randomized trial enrolled and randomized 127 adult patients with acute chikungunya within 72 hours of symptom onset in Thailand. Patients were assigned (1:1) to oral ivermectin (400 µg/kg/day for 3 days) plus standard of care or standard of care alone. Before the 1-month endpoint, 7 patients were lost to follow-up, leaving a finalized complete-case cohort of 120 participants (n = 60 per arm) for primary efficacy analysis. Co-primary outcomes were time to acute joint pain clearance and the proportion of patients with persistent joint pain at 1 month. FINDINGS: Early ivermectin significantly accelerated acute joint pain resolution compared to controls (median 3.5 days [IQR 2, 6] vs 12.0 days [IQR 8, 35]; adjusted hazard ratio (aHR) 3.65, 95% CI 2.28, 5.84; p < 0.0001). Ivermectin was associated with a 92% reduction in the odds of persistent joint pain at 1 month (6.6% vs 30%; adjusted odds ratio (aOR) 0.08, 95% CI 0.03, 0.21; p < 0.0001). It also shortened fever clearance (median 2.0 vs 5.0 days; p < 0.0001) and accelerated viral clearance by day 7. CONCLUSIONS: Early ivermectin intervention within 72 hours of symptom onset significantly accelerates clinical recovery, suppresses viral replication, and profoundly reduces persistent joint pain at 1 month. These findings position ivermectin as a promising, scalable therapeutic strategy against CHIKV. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06259383 (Retrospectively registered on February 20, 2024 prior to thawing bio-banked samples for sequential assays, laboratory assay and final analysis). ClinicalTrials.gov identifier: NCT06259383..

Authors

Institutions

Publication Details

Journal
Emerging Microbes & Infections
Published
2026-11-16
DOI
https://doi.org/10.1080/22221751.2026.2765975
Primary Topic
Mosquito-borne diseases and control
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of Early Ivermectin Administration in Acute Chikungunya Virus Infection: A Multicenter, Open-Label, Randomized Controlled Trial

Sorawit Chittrakarn, Phangard Neamrat, Stefan Fernandez, Porntip Intapiboon et al.
Emerging Microbes & Infections
Mosquito-borne diseases and control
article

Efficacy of Early Ivermectin Administration in Acute Chikungunya Virus Infection: A Multicenter, Open-Label, Randomized Controlled Trial

Sorawit Chittrakarn, Phangard Neamrat, Stefan Fernandez, Porntip Intapiboon, Thanaporn Hortiwakul, Wudtichai Manasatienkij, Pisud Siripaitoon, Taweewun Hunsawong, Smonrapat Surasombatpattana, Piyawan Chinnawirotpisan, Siripen Kanchanasuwan, Nonthanat Tongsengkee, Boonsri Charoenmak, Narongdet Kositpantawong, Sujinda Ruangchan, Nattapat Sangkakul, Tawin Khaimook, Watjanarat Nitchot, Butsaya Thaisomboonsuk, Sarunyou Chusri
article en

Abstract

BACKGROUND: Acute and chronic joint pain is the hallmark of chikungunya virus (CHIKV) infection, often progressing to debilitating persistent joint pain. No approved antiviral therapy is available. We evaluated the clinical and virological efficacy of early ivermectin administration in acute CHIKV infection. METHODS: This open-label, randomized trial enrolled and randomized 127 adult patients with acute chikungunya within 72 hours of symptom onset in Thailand. Patients were assigned (1:1) to oral ivermectin (400 µg/kg/day for 3 days) plus standard of care or standard of care alone. Before the 1-month endpoint, 7 patients were lost to follow-up, leaving a finalized complete-case cohort of 120 participants (n = 60 per arm) for primary efficacy analysis. Co-primary outcomes were time to acute joint pain clearance and the proportion of patients with persistent joint pain at 1 month. FINDINGS: Early ivermectin significantly accelerated acute joint pain resolution compared to controls (median 3.5 days [IQR 2, 6] vs 12.0 days [IQR 8, 35]; adjusted hazard ratio (aHR) 3.65, 95% CI 2.28, 5.84; p < 0.0001). Ivermectin was associated with a 92% reduction in the odds of persistent joint pain at 1 month (6.6% vs 30%; adjusted odds ratio (aOR) 0.08, 95% CI 0.03, 0.21; p < 0.0001). It also shortened fever clearance (median 2.0 vs 5.0 days; p < 0.0001) and accelerated viral clearance by day 7. CONCLUSIONS: Early ivermectin intervention within 72 hours of symptom onset significantly accelerates clinical recovery, suppresses viral replication, and profoundly reduces persistent joint pain at 1 month. These findings position ivermectin as a promising, scalable therapeutic strategy against CHIKV. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06259383 (Retrospectively registered on February 20, 2024 prior to thawing bio-banked samples for sequential assays, laboratory assay and final analysis). ClinicalTrials.gov identifier: NCT06259383..

Emerging Microbes & Infections
Prince of Songkla University (TH), Hatyai Hospital (TH), Armed Forces Research Institute of Medical Science (TH), Songkhla Hospital (TH), Trang Hospital (TH)
Faculty of Medicine, Prince of Songkla University
Good health and well-being
Mosquito-borne diseases and control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon